Neoadjuvant Study of DV Plus Toripalimab in Combination or Sequence With Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Disitamab Vedotin Injection （18 weeks）|DRUG: Toripalimab （18weeks）|DRUG: Carboplatin|DRUG: Disitamab Vedotin Injection （12 weeks）|DRUG: Sequential Epirubicin|DRUG: Sequential CTX|DRUG: Toripalimab （12weeks）
Sponsor: RemeGen Co., Ltd.